Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nuclear transcription factor c-Myb, which is highly expressed in hematopoietic cells, has been shown to be functional in NIH 3T3 cells: cells that do not possess detectable levels of c-Myb. To identify endogenous target genes of c-Myb in fibroblasts, RNA isolated from NIH 3T3 cells stably transfected with a full-length or a dominant negative c-myb construct (GREMyb and GREMEn, respectively) was subjected to differential display analysis. 5'-Rapid amplification of cDNA ends of a selected band, sequencing, and a nucleotide homology search led to the identification of thrombospondin 2 (
TSP
2) as the gene product repressed in GREMyb and induced in GREMEn cells. The pattern of
TSP
2 expression during the cell cycle was consistent with c-myb-dependent regulation. The possibility that the identified transcript was
TSP
1, a homologous product known to be repressed by v-Src,
c-Jun
, and v-Myc, was ruled out by using a
TSP
2-specific DNA probe and by showing a distinct pattern of regulation of
TSP
1 and
TSP
2 expression. Nuclear run-on and
TSP
2 promoter-reporter (chloramphenicol acetyltransferase) assays showed similar transcriptional levels in GREMyb and NIH 3T3 cells. However, mRNA stability studies showed a much shorter
TSP
2 mRNA half-life in GREMyb compared with wild type NIH 3T3 cells, suggesting that c-myb affects
TSP
2 expression via a post-transcriptional mechanism. The implications of a protooncogene-mediated suppression of
TSP
expression are discussed.
...
PMID:Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. 969 6
Thrombospondin-1
(
TSP-1
), a multifunctional extracellular matrix protein, inhibits neovascularization and is implicated in the regression of tumor growth and metastasis. We found that the synthesis of
TSP-1
in porcine aortic endothelial (PAE) cells was decreased in a dose-dependent manner by phorbol 12-myristate 13-acetate (PMA) treatment in porcine aortic endothelial (PAE) cells. In this study, a responsive site on the
TSP-1
promotor affected by PMA treatment in PAE was characterized. The level of
TSP-1
mRNA was also decreased by PMA after 1 h and persisted that way for at least 24 h. PMA treatment and
c-Jun
overexpression suppressed the transcription of
TSP-1
promotor-luciferase reporter gene. A deletion between -767 and -657 on the
TSP-1
promotor neutralized the PMA-induced down-regulation. In addition, oligo a (-767 approximately -723) was responsive to PMA-induced repression, while oligo b (-734 approximately -689) and c (-700 approximately -656) was not. Electrophoretic mobility shift assays showed that this PMA responsive element specifically bound a nuclear protein and that the binding activity was diminished by PMA treatment in PAE cells but not in Hep 3B cells. In supershift assay, potential regulatory elements in this region, SP1 and GATA-1, were not responsive to the inhibition of
TSP-1
expression by PMA. Our results suggest that the repression of
TSP-1
synthesis by PMA is mediated by blocking a particular unknown nuclear protein binding to the responsive site (-767 approximately -735), which is regulated by
c-Jun
.
...
PMID:Responsive site on the thrombospondin-1 promotor to down-regulation by phorbol 12-myristate 13-acetate in porcine aortic endothelial cells. 1104 44
Thrombospondin-1
(
TSP-1
) is a homotrimeric glycoprotein synthesized in a variety of normal and transformed cells, and secreted into the extracellular matrix. Based on its known effects on the tumor and endothelial cells,
TSP-1
was implicated in the tumor growth and metastasis. In the present study, we have demonstrated the expression of
TSP-1
in the human hepatocarcinoma cell lines.
TSP-1
was detected in human hepatocarcinoma SK-HEP-1, Hep 3B and immortalized human liver Chang cells. Using two different cell lines, SK-HEP-1 and Hep 3B cells, we have studied effects of phorbol 12-myristate 13-acetate (PMA) on
TSP-1
expression.
TSP-1
synthesis was stimulated by PMA in both cell lines. When the cells were treated with PMA, the
TSP-1
mRNA started to increase at 30 min and reached the maximal level at 6 h.
TSP-1
induction by PMA was completely inhibited by the pre-treatment of 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7), a potent protein kinase C inhibitor. A
TSP-1
promoter-luciferase reporter gene was transcriptionally activated by PMA, as well as by the expression of
c-Jun
. Among three putative AP-1 recognition sites on the
TSP-1
promoter, a deletion of the 1st and 2nd sites caused loss of PMA-induced upregulation, while the 3rd site deletion showed no effect. In subsequent experiments, both the recombinant
c-Jun
and nuclear proteins induced by PMA have a stronger binding affinity for the 2nd AP-1 recognition site than the 1st and 3rd ones. Our study demonstrated that
TSP-1
could be expressed and secreted by human hepatoma cell lines and its expression could be effectively regulated by PMA. We also suggest that AP-1 binding activity through the protein kinase C activation is a critical event for the
TSP-1
gene expression and consequently affects production and processing of the protein.
...
PMID:Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1. 1121 60
Thrombospondin-1
(
TSP-1
) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by
TSP-1
did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather,
TSP-1
induced a rapid and transient activation of
c-Jun
N-terminal kinases (JNK). JNK activation by
TSP-1
required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from
TSP-1
that act exclusively via CD36.
TSP-1
inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by
TSP-1
.
...
PMID:c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. 1142 95
Thrombospondin-1
(
TSP-1
), a multifunctional protein that is able to function as a negative regulator of solid tumor progression and angiogenesis, is normally present at a very low level but rapidly elevated in pathological tissues. To understand the cellular regulation of
TSP-1
expression, the mode of it's expression in Hep3B, SK-HEP-1, and porcine aortic endothelial (PAE) cells was examined in the presence of all-trans retinoic acid (ATRA), interleukin-6 (IL-6), interferon-gamma (IFN-gamma), or phorbol 12-myristate 13-acetate (PMA). ATRA or IL-6 induced a dose-dependent increase of
TSP-1
protein and mRNA levels in PAE cells, while they negatively regulated
TSP-1
expression in the Hep3B and SK-HEP-1 cells. In contrast, PMA showed just the opposite effects on the
TSP-1
expression in the same cells. IFN-gamma had little effect on
TSP-1
level in Hep3B and PAE cells. The
TSP-1
expression in SK-HEP-1 cells by these agents showed a close resemblance to that of liver cells rather than that of the endothelial cell line. Possible
TSP-1
promoter-mediated responses by ATRA, IL-6, IFN-gamma, or PMA in Hep3B and PAE cells examined with luciferase activity of
TSP
-LUC reporter plasmid showed that levels of
TSP-1
promoter activity were lower than that of the expressed
TSP-1
protein and mRNA levels. Transfection of
c-Jun
and/or RARalpha expression vectors into Hep3B and PAE cells resulted in the enhanced
TSP-1
promoter activity as well as the increments of of its protein and mRNA level. These results suggest that regulatory agents-induced
TSP-1
expression may be attributed to mRNA stability and/or translational activation in concert with transcriptional activation and
TSP-1
expression may be independently controlled via each signal pathway stimulated by PMA or ATRA.
...
PMID:Cell-type specific regulation of thrombospondin-1 expression and its promoter activity by regulatory agents. 1164 46
Thrombospondin-1
(
TSP-1
) level is tightly regulated at the transcriptional level. To determine the detailed molecular mechanisms of
TSP-1
expression, nine serial 5'-deletion constructs of the human genomic tsp-1 promoter (nucleotides -2,220 to +756) were prepared, inserted into luciferase reporter plasmids, and transiently transfected into the Hep3B human hepatocarcinoma cell. Among the nine 5'-deletion constructs, pTSP-Luc-4 (-767 approximately +756) had consistently decreased luciferase activity with or without PMA stimulation, whereas a further truncated construct [pTSP-Luc-4' (-407 approximately +756)] had increased levels of expression. By searching the nucleotides from -767 to -407, a consensus binding sequence (5'-CCATTTT-3') for the repressor Yin Yang-1 (YY-1) at nucleotide -440 was identified. The suppression induced by this site was weakened in the presence of the region upstream of nucleotide -767 (pTSP-Luc-1 and -2). Nuclear protein directly bound to an oligonucleotide containing the repressive YY-1 sequence but the binding capacity of the sequence was decreased by the increased
c-Jun
levels. Moreover, proteins immunoprecipitated with anti-YY-1 revealed an interaction between
c-Jun
and YY-1 factor. These data suggest that the repressive YY-1 site of the tsp-1 promoter could not be functional via activating positive cis-elements on the upstream from this site and weakened via
c-Jun
/YY-1 interactions.
...
PMID:Weakening of the repressive YY-1 site on the thrombospondin-1 promoter via c-Jun/YY-1 interaction. 1536 49
High-throughput genomic technology identified an association between a single nucleotide polymorphism (SNP), a proline (P387) rather than the predominant alanine (A387) at position 387 in thrombospondin-4 (TSP-4) and premature myocardial infarction. The inflammatory hypothesis of atherosclerosis invokes a prominent role of leukocytes and cytokines in pathogenesis. As the expression of
TSP
-4 by vascular cells permits its exposure to circulating leukocytes, the interactions of human neutrophils (polymorphonuclear leukocytes [PMNs]) with both
TSP
-4 variants were investigated. Phorbol 12-myristate 13-acetate (PMA)-stimulated PMNs adhered and migrated well and equally on the
TSP
-4 variants. Integrin alpha(M)beta2 was identified as the
TSP
-4 receptor mediating these responses, and the 3 epidermal growth factor (EGF)-like domains of
TSP
-4 harboring the SNPs interacted with the alpha(M)I-domain. Despite the similarity in these responses, the P387 variant induced more robust tyrosine phosphorylation of the stress-related mitogen-activated protein kinases (MAPKs): p38MAPK and
c-Jun
NH2-terminal kinase (JNK), as well as signal transducer and activator of transcription-1 (STAT1) and heat shock protein 27 (HSP27) than the A387 variant. Additionally, cells adherent to P387
TSP
-4 variant released 4-fold more H2O2 and secreted 2-fold more interleukin 8 (IL-8) as compared with the A387. H2O2 release and p38MAPK activation were totally inhibited by blockade of alpha(M)beta2. Thus, alpha(M)beta2 plays a central role in proinflammatory activities of
TSP
-4 (P387) and may contribute to the prothrombotic phenotype associated with this variant.
...
PMID:Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. 1609 85